28 results
8-K
EX-10.1
BLFS
Biolife Solutions Inc
19 Oct 23
Entry into a Material Definitive Agreement
5:07pm
or its Subsidiaries’ employees is a member of a union that relates to such employee’s relationship with the Company or such Subsidiary, and neither
8-K
EX-99.1
BLFS
Biolife Solutions Inc
31 Aug 23
Regulation FD Disclosure
5:15pm
(US) and the European Union (EU) thus far in the calendar year 2023 FDA is set to potentially approve up to 9 cell and gene therapies in 2023
8-K
EX-2.1
BLFS
Biolife Solutions Inc
25 Mar 21
Entry into a Material Definitive Agreement
5:27pm
representative of any of the employees of any Target Company, and the Company has no Knowledge of any activities or proceedings of any labor union
8-K
EX-2.1
luj56o
24 Sep 20
Entry into a Material Definitive Agreement
5:04pm
8-K
EX-10.1
gt9in5e1cd jp
8 Jul 20
Entry into a Material Definitive Agreement
8:54am
424B5
qa5nivsz c4ijel
6 Jul 20
Prospectus supplement for primary offering
6:06am
424B5
i18ditabny d2glp
1 Jul 20
Prospectus supplement for primary offering
4:55pm
8-K
EX-2.1
gvhx9
15 Nov 19
Completion of Acquisition or Disposition of Assets
5:25pm
8-K
EX-2.1
8b1z9wl
13 Aug 19
Completion of Acquisition or Disposition of Assets
4:34pm
8-K
EX-2.1
7y0nai
5 Apr 19
Completion of Acquisition or Disposition of Assets
5:19pm
424B3
1ko1dluyiq vlv98gr
26 Mar 14
Prospectus supplement
12:00am
8-K
EX-10.1
l4da0
20 Mar 14
BioLife Solutions Announces Pricing of $15.4 Million Public Offering
12:00am
8-K
EX-10.2
3u5wvg x6
20 Mar 14
BioLife Solutions Announces Pricing of $15.4 Million Public Offering
12:00am